Skip to main content

Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).

Publication ,  Conference
Catenacci, DVT; Park, H; Uronis, HE; Kang, Y-K; Lacy, J; Enzinger, PC; Park, SH; Lee, KW; Ng, MCH; Gold, PJ; Yen, J; Franovic, A; Kelly, RJ ...
Published in: Journal of Clinical Oncology
May 20, 2018

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2018

Volume

36

Issue

15_suppl

Start / End Page

4030 / 4030

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Catenacci, D. V. T., Park, H., Uronis, H. E., Kang, Y.-K., Lacy, J., Enzinger, P. C., … Bang, Y.-J. (2018). Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T). In Journal of Clinical Oncology (Vol. 36, pp. 4030–4030). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.4030
Catenacci, Daniel V. T., Haeseong Park, Hope Elizabeth Uronis, Yoon-Koo Kang, Jill Lacy, Peter C. Enzinger, Se Hoon Park, et al. “Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).” In Journal of Clinical Oncology, 36:4030–4030. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.4030.
Catenacci DVT, Park H, Uronis HE, Kang Y-K, Lacy J, Enzinger PC, et al. Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 4030–4030.
Catenacci, Daniel V. T., et al. “Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 4030–4030. Crossref, doi:10.1200/jco.2018.36.15_suppl.4030.
Catenacci DVT, Park H, Uronis HE, Kang Y-K, Lacy J, Enzinger PC, Park SH, Lee KW, Ng MCH, Gold PJ, Yen J, Franovic A, Kelly RJ, Wynter-Horton A, Li D, Muth J, Baughman JE, Hong S, Davidson-Moncada JK, Bang Y-J. Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 4030–4030.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2018

Volume

36

Issue

15_suppl

Start / End Page

4030 / 4030

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences